PUR-1800 is under clinical development by Pulmatrix and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PUR-1800’s likelihood of approval (LoA) and phase transition for Chronic Obstructive Pulmonary Disease (COPD) took place on 20 Dec 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PUR-1800 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PUR-1800 overview

PUR-1800 is under development for the treatment of chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis. The drug candidate is a small molecule. It acts by targeting p38 MAP kinases (p38MAPK), Src kinases,and Syk kinases. The drug candidate is developed based on iSPERSE technology. It is an narrow-spectrum kinase inhibitor (NSKI). The drug candidate is administerd as nasal drops and as inhalation via dry powder inhaler.

It was under development for the treatment of chronic obstructive pulmonary disease (COPD), respiratory syncytial virus (RSV) infections, seasonal allergic rhinitis and lung cancer.

Pulmatrix overview

Pulmatrix, formerly Ruthigen is a clinical stage biopharmaceutical company that discovers and develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline products using its proprietary dry powder delivery technology, iSPERSE. Its pipeline products include PUR1900, an anti-fungal compound which is in Phase 1 clinical trials intended to treat allergic bronchopulmonary aspergillosis in severe asthmatics and cystic fibrosis patients; PUR1800, a narrow-spectrum kinase inhibitor intended for the treatment of patients with chronic obstructive pulmonary disease (COPD); PUR5700, for COPD, idiopathic pulmonary fibrosis and asthma; and PUR0200, a long-acting muscarinic antagonist drug candidate for COPD. Pulmatrix is headquartered in Lexington, Massachusetts, the US

Quick View PUR-1800 LOA Data

Report Segments
  • Innovator
Drug Name
  • PUR-1800
Administration Pathway
  • Inhalational
  • Nasal
Therapeutic Areas
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: Pulmatrix
  • Originator: RespiVert
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.